The analysis found that patients taking tirzepatide were significantly more likely to achieve weight loss: Those taking tirzepatide were 1.8 times more likely than those taking semaglutide to achieve 5% weight loss, 2.5 times more likely than those taking semaglutide to achieve 10% weight loss, And 3.2 times more likely than those taking semaglutide to achieve 15% weight loss
Susan Spratt, an endocrinologist and the senior medical director of the Population Health Management Office at Duke Health in North Carolina, who was not involved in the studies, applauded the research, saying the findings show that obesity is not a vanity issue. This is about treating a major health problem that reduces significant morbidity and mortality, she said
The combination of semaglutide-delayed transit and sugar alcohol fermentation creates significant gas
Media and Third-Party Validation Major issues LifeRx displays media logos in a has been featured on section, but none link to actual articles, and most listings could not be verified
Read our full list of the best clinics offering Mounjaro
